Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Westlake Eye Specialists
With
Sengi
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patients 18 years and older
Diagnosed with normal tension glaucoma based on the following:
* IOP ≤ 21mmHg
* Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma
* Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year
* Open angles assessed by gonioscopy
Have been on latanoprost monotherapy for at least 6 weeks
You may not be if
Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
Other forms of secondary glaucoma.
Patients with abnormal anterior segment examination other than cataract will be excluded from the study.
Patients who have had incisional surgery for glaucoma (eg: MIGs).
Patients with refractory CME or CME persisting 3 months or more.
Children, cognitive impaired and critically ill subjects will not be enrolled.
Central Corneal Thickness (CCT) ≤ 500.
Prior allergy to brimonidine or netarsudil, and known to have previously failed either brimonidine or netarsudil.
Ocular surgery (e.g., cataract, laser, refractive) during the study or 1 year prior to entering the study.
The principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial.
Clareo Health | Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost
